| Supplemental Balance Sheet Disclosures [Text Block] |
|
3.
|
Balance Sheet Components
|
Prepaid Expenses and Other Current Assets – Prepaid expenses and other current assets consist of the following:
| |
|
June 30,
2026
|
|
|
December 31,
2025
|
|
|
Prepaid clinical trial costs
|
|
$ |
832,889 |
|
|
$ |
1,197,679 |
|
|
Prepaid insurance premiums
|
|
|
112,681 |
|
|
|
165,067 |
|
|
Prepaid rent
|
|
|
25,974 |
|
|
|
16,000 |
|
|
Prepaid contract manufacturing costs
|
|
|
- |
|
|
|
783,321 |
|
|
Other prepaid expenses
|
|
|
60,333 |
|
|
|
66,843 |
|
|
Total prepaid expenses and other current assets
|
|
$ |
1,031,877 |
|
|
$ |
2,228,910 |
|
Property and Equipment – Property and equipment consist of the following:
| |
|
June 30,
2026
|
|
|
December 31,
2025
|
|
|
Equipment and furnishings
|
|
$ |
512,437 |
|
|
$ |
512,437 |
|
|
Accumulated depreciation and amortization
|
|
|
(427,759 |
) |
|
|
(403,607 |
) |
|
Total property and equipment, net
|
|
$ |
84,678 |
|
|
$ |
108,830 |
|
Other Assets – Other assets consist of the following:
| |
|
June 30,
2026
|
|
|
December 31,
2025
|
|
|
Prepaid technology license fees
|
|
$ |
50,000 |
|
|
$ |
50,000 |
|
|
Deposits
|
|
|
19,947 |
|
|
|
36,947 |
|
|
Total other assets
|
|
$ |
69,947 |
|
|
$ |
86,947 |
|
Accrued Expenses – Accrued expenses consist of the following:
| |
|
June 30,
2026
|
|
|
December 31,
2025
|
|
|
Payroll-related liabilities
|
|
$ |
237,835 |
|
|
$ |
181,584 |
|
|
Accrued clinical trial costs
|
|
|
393,835 |
|
|
|
587,303 |
|
|
Other accrued expenses
|
|
|
93,000 |
|
|
|
113,929 |
|
|
Total accrued expenses
|
|
$ |
724,670 |
|
|
$ |
882,816 |
|
|
3. Balance Sheet Components
Prepaid expenses and other current assets consist of the following as of December 31, 2025 and 2024:
| |
|
2025
|
|
|
2024
|
|
|
Prepaid clinical trial costs
|
|
$ |
1,197,679 |
|
|
$ |
1,524,813 |
|
|
Prepaid insurance premiums
|
|
|
165,067 |
|
|
|
220,675 |
|
|
Prepaid rent
|
|
|
16,000 |
|
|
|
13,045 |
|
|
Prepaid contract manufacturing costs
|
|
|
783,321 |
|
|
|
- |
|
|
Other
|
|
|
66,843 |
|
|
|
10,000 |
|
|
Total prepaid expenses
|
|
$ |
2,228,910 |
|
|
$ |
1,768,533 |
|
Property and equipment consist of the following as of December 31, 2025 and 2024:
| |
|
2025
|
|
|
2024
|
|
|
Equipment and furnishings
|
|
$ |
512,437 |
|
|
$ |
795,411 |
|
|
Leasehold improvements
|
|
|
- |
|
|
|
115,605 |
|
|
Total property and equipment
|
|
|
512,437 |
|
|
|
911,016 |
|
|
Accumulated depreciation and amortization
|
|
|
(403,607 |
) |
|
|
(761,042 |
) |
|
Total property and equipment, net
|
|
$ |
108,830 |
|
|
$ |
149,974 |
|
Depreciation expense was $68,756 and $80,368 during the years ended December 31, 2025 and 2024, respectively.
Other assets consist of the following as of December 31, 2025 and 2024:
| |
|
2025
|
|
|
2024
|
|
|
Prepaid technology license fees
|
|
$ |
50,000 |
|
|
$ |
60,000 |
|
|
Deposits
|
|
|
36,947 |
|
|
|
11,010 |
|
|
Total other assets
|
|
$ |
86,947 |
|
|
$ |
71,010 |
|
Accrued expenses consist of the following as of December 31, 2025 and 2024:
| |
|
2025
|
|
|
2024
|
|
|
Payroll-related liabilities
|
|
$ |
181,584 |
|
|
$ |
986,691 |
|
|
Accrued clinical trial costs
|
|
|
587,303 |
|
|
|
200,881 |
|
|
Other accrued expenses
|
|
|
113,929 |
|
|
|
70,000 |
|
|
Total accrued expenses
|
|
$ |
882,816 |
|
|
$ |
1,257,572 |
|
|